首页> 外文期刊>Open Forum Infectious Diseases >Safety of Outpatient Parenteral Antimicrobial Therapy in Nonagenarians
【24h】

Safety of Outpatient Parenteral Antimicrobial Therapy in Nonagenarians

机译:犹太人外科肠外抗菌治疗的安全性

获取原文
           

摘要

BackgroundAlthough widely accepted for adults, the safety of outpatient parenteral antimicrobial therapy (OPAT) in very old patients has not been examined.MethodsNonagenarians (age?≥90 years) discharged from the hospital on OPAT over a 5-year period were identified from the Cleveland Clinic OPAT Registry. Three matched controls (90 years) were selected for each nonagenarian. Times to OPAT-related emergency department (ED) visit and OPAT-related readmission were compared across the 2 groups in multivariable subdistribution proportional hazards competing risks regression models. Incidence of adverse drug events and vascular access complications were compared using negative binomial regression.ResultsOf 126 nonagenarians and 378 controls, 7 were excluded for various reasons. Among the remaining 497 subjects, 306 (62%) were male, 311 (63%) were treated for cardiovascular or osteoarticular infections, and 363 (73%) were discharged to a residential health care facility. The mean (SD) ages of nonagenarians and controls were 92 (2) and 62 (16) years, respectively. Compared with matched controls, being a nonagenarian was not associated with increased risk of OPAT-related ED visit (hazard ratio [HR], 0.77; 95% CI, 0.33–1.80; P?=?.55), OPAT-related readmission (HR, 0.78; 95% CI, 0.28–2.16; P?=?.63), adverse drug event from OPAT medications (incidence rate ratio [IRR], 1.00; 95% CI, 0.43–2.17; P?=?.99), or vascular access complications (IRR, 0.66; 95% CI, 0.27–1.51; P?=?.32). Nonagenarians had a higher risk of death overall (HR, 2.64; 95% CI, 1.52–4.58; P??.001), but deaths were not from OPAT complications.ConclusionsCompared with younger patients, OPAT in nonagenarians is not associated with higher risk of OPAT-related complications. OPAT can be provided as safely to nonagenarians as to younger patients.
机译:背景技术虽然是成人的广泛接受,但尚未审查过门诊肠胃外抗菌治疗(OPAT)的安全性尚未进行检查。从克利夫兰确定了从医院从医院出院的奥纳尼亚尼人(年龄?≥90岁)诊所OPAT注册处。为每个义主进行选择三个匹配的控制(<90年)。与OPAT相关的急诊部门(ED)访问和OPAT相关的再生中的奥帕特相关的再分布式危险竞争风险回归模型的竞争风险。使用阴性二项式回归比较不良药物事件和血管接入并发症的发病率。结果是126个少年和378个对照,7例被排除出于各种原因。剩余的497个受试者中,306(62%)是男性,治疗311(63%),用于心血管或骨质性感染,363(73%)排放到住宅保健机构。犹太人和对照的平均值(SD)年龄分别为92(2)和62(16)岁。与匹配的对照相比,是一个巨大的诺贝拉特与奥卡斯相关的ed的风险增加(危险比[hr],0.77; 95%ci,0.33-1.80; p?= 35),opat相关的readmission( HR,0.78; 95%CI,0.28-2.16; p?=β.63),来自OPAT药物的不良药物事件(发病率比[IRR],1.00; 95%CI,0.43-2.17; P?= 99 )或血管接入并发症(IRR,0.66; 95%CI,0.27-1.51; P?= 32)。少年亚洲人的死亡风险较高(HR,2.64; 95%CI,1.52-4.58; p?<〜001),但死亡不是从OPAT并发症的患者。与年轻患者的结论,犹太人的opat与更高Opat相关并发症的风险。 OPAT可以安全地向年轻患者安全提供。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号